Published in EMBO Mol Med on January 25, 2012
Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation (2013) 2.57
Induced pluripotent stem cells: the new patient? Nat Rev Mol Cell Biol (2012) 2.50
Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models. PLoS One (2015) 1.53
Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics. J Gen Physiol (2013) 1.44
Flecainide exerts paradoxical effects on sodium currents and atrial arrhythmia in murine RyR2-P2328S hearts. Acta Physiol (Oxf) (2015) 1.41
Concise review: maturation phases of human pluripotent stem cell-derived cardiomyocytes. Stem Cells (2013) 1.28
Induced pluripotent stem cell-derived cardiomyocytes: boutique science or valuable arrhythmia model? Circ Res (2013) 1.27
Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. EMBO J (2013) 1.24
Induced pluripotent stem cells in cardiovascular drug discovery. Circ Res (2013) 1.22
Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations. PLoS One (2012) 1.19
Induced pluripotent stem cell-derived cardiomyocytes in studies of inherited arrhythmias. J Clin Invest (2013) 1.17
Ryanodine receptor blockade reduces amyloid-β load and memory impairments in Tg2576 mouse model of Alzheimer disease. J Neurosci (2012) 1.16
Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias. Front Physiol (2012) 1.15
Induced pluripotent stem cells: at the heart of cardiovascular precision medicine. Nat Rev Cardiol (2016) 1.13
Ca2+ signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects. Cell Calcium (2013) 1.07
Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes. Circ Res (2015) 1.02
CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia. Cell Death Dis (2013) 1.01
Induced pluripotent stem cell-derived cardiomyocytes for cardiovascular disease modeling and drug screening. Stem Cell Res Ther (2013) 1.01
Pluripotent stem cell models of human heart disease. Cold Spring Harb Perspect Med (2013) 1.01
Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nat Commun (2015) 0.99
Current status of drug screening and disease modelling in human pluripotent stem cells. Bioessays (2012) 0.98
New and TALENted genome engineering toolbox. Circ Res (2013) 0.96
Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes. Circ Res (2015) 0.96
Modeling Timothy syndrome with iPS cells. J Cardiovasc Transl Res (2013) 0.95
Antisense-mediated exon skipping: a therapeutic strategy for titin-based dilated cardiomyopathy. EMBO Mol Med (2015) 0.93
Systems biology and cardiac arrhythmias. Lancet (2012) 0.92
Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform. Biochim Biophys Acta (2015) 0.92
Cardiomyocytes derived from human induced pluripotent stem cells as models for normal and diseased cardiac electrophysiology and contractility. Prog Biophys Mol Biol (2012) 0.89
Oxidation of ryanodine receptor (RyR) and calmodulin enhance Ca release and pathologically alter, RyR structure and calmodulin affinity. J Mol Cell Cardiol (2015) 0.88
Calcium signalling of human pluripotent stem cell-derived cardiomyocytes. J Physiol (2013) 0.87
Gene mutations in cardiac arrhythmias: a review of recent evidence in ion channelopathies. Appl Clin Genet (2013) 0.87
The investigation of sudden arrhythmic death syndrome (SADS)-the current approach to family screening and the future role of genomics and stem cell technology. Front Physiol (2013) 0.86
Modeling heart disease in a dish: from somatic cells to disease-relevant cardiomyocytes. Trends Cardiovasc Med (2013) 0.86
Concise review: drug discovery in the age of the induced pluripotent stem cell. Stem Cells Transl Med (2014) 0.86
Modelling sarcomeric cardiomyopathies in the dish: from human heart samples to iPSC cardiomyocytes. Cardiovasc Res (2015) 0.85
Translation of Human-Induced Pluripotent Stem Cells: From Clinical Trial in a Dish to Precision Medicine. J Am Coll Cardiol (2016) 0.85
Monitoring Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes with Genetically Encoded Calcium and Voltage Fluorescent Reporters. Stem Cell Reports (2015) 0.84
Cardiac disease modeling using induced pluripotent stem cell-derived human cardiomyocytes. World J Stem Cells (2015) 0.83
Essential Role of Calmodulin in RyR Inhibition by Dantrolene. Mol Pharmacol (2015) 0.83
Human pluripotent stem cell-derived cardiomyocytes as research and therapeutic tools. Biomed Res Int (2014) 0.83
Modelling human channelopathies using induced pluripotent stem cells: a comprehensive review. Stem Cells Int (2013) 0.82
Modeling Catecholaminergic Polymorphic Ventricular Tachycardia using Induced Pluripotent Stem Cell-derived Cardiomyocytes. Rambam Maimonides Med J (2012) 0.82
Ryanodine receptors: physiological function and deregulation in Alzheimer disease. Mol Neurodegener (2014) 0.82
Identification and characterization of a transient outward K+ current in human induced pluripotent stem cell-derived cardiomyocytes. J Mol Cell Cardiol (2013) 0.82
Cardiomyopathy in a dish: using human inducible pluripotent stem cells to model inherited cardiomyopathies. J Card Fail (2015) 0.82
Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations. J Cell Mol Med (2015) 0.81
Automated Electrophysiological and Pharmacological Evaluation of Human Pluripotent Stem Cell-Derived Cardiomyocytes. Stem Cells Dev (2016) 0.80
Barth Syndrome: From Mitochondrial Dysfunctions Associated with Aberrant Production of Reactive Oxygen Species to Pluripotent Stem Cell Studies. Front Genet (2016) 0.80
Cardiovascular Disease Modeling Using Patient-Specific Induced Pluripotent Stem Cells. Int J Mol Sci (2015) 0.80
The current status of iPS cells in cardiac research and their potential for tissue engineering and regenerative medicine. Stem Cell Rev (2014) 0.80
Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and drug screening. Biotechnol Adv (2016) 0.79
Prospective in vitro models of channelopathies and cardiomyopathies. Stem Cells Int (2012) 0.79
Generation of human cardiomyocytes: a differentiation protocol from feeder-free human induced pluripotent stem cells. J Vis Exp (2013) 0.79
Dantrolene: from better bacon to a treatment for ventricular fibrillation. Circulation (2014) 0.79
Inherited heart disease - what can we expect from the second decade of human iPS cell research? FEBS Lett (2016) 0.77
Induced pluripotent stem cells for cardiovascular disease: from product-focused disease modeling to process-focused disease discovery. Regen Med (2015) 0.77
Calcium signaling in human stem cell-derived cardiomyocytes: Evidence from normal subjects and CPVT afflicted patients. Cell Calcium (2015) 0.77
Recapitulating long-QT syndrome using induced pluripotent stem cell technology. Pediatr Cardiol (2012) 0.77
CaMKII-dependent phosphorylation of RyR2 promotes targetable pathological RyR2 conformational shift. J Mol Cell Cardiol (2016) 0.77
Prospects for In Vitro Myofilament Maturation in Stem Cell-Derived Cardiac Myocytes. Biomark Insights (2015) 0.77
Human induced pluripotent stem cell-derived versus adult cardiomyocytes: an in silico electrophysiological study on effects of ionic current block. Br J Pharmacol (2015) 0.77
Generation of highly purified human cardiomyocytes from peripheral blood mononuclear cell-derived induced pluripotent stem cells. PLoS One (2015) 0.77
Maturation status of sarcomere structure and function in human iPSC-derived cardiac myocytes. Biochim Biophys Acta (2015) 0.76
Pluripotent stem cells as a platform for cardiac arrhythmia drug screening. Curr Treat Options Cardiovasc Med (2014) 0.76
Human heart disease: lessons from human pluripotent stem cell-derived cardiomyocytes. Cell Mol Life Sci (2017) 0.75
Patient Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Development and Screening In Catecholaminergic Polymorphic Ventricular Tachycardia. J Atr Fibrillation (2016) 0.75
Cardiac regeneration using HLA-matched induced pluripotent stem cells-no monkey business, but still a long and winding road ahead. J Thorac Dis (2017) 0.75
Modeling Inherited Arrhythmia Disorders Using Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Circ J (2016) 0.75
Young at Heart: Pioneering Approaches to Model Nonischaemic Cardiomyopathy with Induced Pluripotent Stem Cells. Stem Cells Int (2016) 0.75
Patient-Specific Induced Pluripotent Stem Cell Models: Generation and Characterization of Cardiac Cells. Methods Mol Biol (2016) 0.75
Catecholaminergic polymorphic ventricular tachycardia: An exciting new era. Ann Pediatr Cardiol (2016) 0.75
Can Human Pluripotent Stem Cell-Derived Cardiomyocytes Advance Understanding of Muscular Dystrophies? J Neuromuscul Dis (2016) 0.75
A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses. Dis Model Mech (2016) 0.75
A Systemized Approach to Investigate Ca(2+) Synchronization in Clusters of Human Induced Pluripotent Stem-Cell Derived Cardiomyocytes. Front Cell Dev Biol (2016) 0.75
Dantrolene suppresses spontaneous Ca2+ release without altering excitation-contraction coupling in cardiomyocytes of aged mice. Am J Physiol Heart Circ Physiol (2014) 0.75
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Afford New Opportunities in Inherited Cardiovascular Disease Modeling. Cardiol Res Pract (2016) 0.75
Clinical Potentials of Cardiomyocytes Derived from Patient-Specific Induced Pluripotent Stem Cells. J Clin Med (2014) 0.75
Induced pluripotent stem cell potential in medicine, specifically focused on reproductive medicine. Front Surg (2014) 0.75
Novel Analysis Software for Detecting and Classifying Ca2+ Transient Abnormalities in Stem Cell-Derived Cardiomyocytes. PLoS One (2015) 0.75
Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia. Cell Death Dis (2016) 0.75
Cryopreservation of Human Pluripotent Stem Cell-Derived Cardiomyocytes: Strategies, Challenges, and Future Directions. Adv Exp Med Biol (2016) 0.75
Electrophysiological Analysis of human Pluripotent Stem Cell-derived Cardiomyocytes (hPSC-CMs) Using Multi-electrode Arrays (MEAs). J Vis Exp (2017) 0.75
Calcium handling and ventricular tachyarrhythmias. Wien Med Wochenschr (2012) 0.75
Murine Electrophysiological Models of Cardiac Arrhythmogenesis. Physiol Rev (2017) 0.75
The Promise and Challenge of Induced Pluripotent Stem Cells for Cardiovascular Applications. JACC Basic Transl Sci (2016) 0.75
Calcium Signaling and Cardiac Arrhythmias. Circ Res (2017) 0.75
Human pluripotent stem cell models of cardiac disease: from mechanisms to therapies. Dis Model Mech (2017) 0.75
From Bench to Market: Preparing Human Pluripotent Stem Cells Derived Cardiomyocytes for Various Applications. Int J Stem Cells (2017) 0.75
Tissue Engineering Approaches in the Design of Healthy and Pathological In Vitro Tissue Models. Front Bioeng Biotechnol (2017) 0.75
Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell (2007) 101.42
A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem (1985) 90.20
Calcium sparks: elementary events underlying excitation-contraction coupling in heart muscle. Science (1993) 17.63
PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell (2000) 10.25
Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med (2010) 9.19
Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation (2001) 5.68
FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell (2003) 4.68
Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature (2010) 4.38
Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature (2011) 4.10
Sarcoplasmic reticulum Ca(2+) release causes myocyte depolarization. Underlying mechanism and threshold for triggered action potentials. Circ Res (2000) 3.78
Enhanced store overload-induced Ca2+ release and channel sensitivity to luminal Ca2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death. Circ Res (2005) 3.34
Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model. Circ Res (2006) 2.81
Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ Res (2002) 2.66
Dantrolene--a review of its pharmacology, therapeutic use and new developments. Anaesthesia (2004) 2.50
Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harb Perspect Biol (2010) 2.46
Leaky Ca2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. J Clin Invest (2008) 2.45
Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes. Circ Res (2003) 2.44
Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis. Circ Res (2011) 2.37
Kinetics of FKBP12.6 binding to ryanodine receptors in permeabilized cardiac myocytes and effects on Ca sparks. Circ Res (2010) 2.29
Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor. J Am Coll Cardiol (2009) 2.21
Modulation of ryanodine receptor by luminal calcium and accessory proteins in health and cardiac disease. Cardiovasc Res (2007) 2.17
Macromolecular complexes regulating cardiac ryanodine receptor function. J Mol Cell Cardiol (2004) 1.93
The amino-terminal disease hotspot of ryanodine receptors forms a cytoplasmic vestibule. Nature (2010) 1.79
Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor. Circ Res (2010) 1.61
Postulated role of interdomain interaction within the ryanodine receptor in Ca(2+) channel regulation. J Biol Chem (2000) 1.59
Investigating monogenic and complex diseases with pluripotent stem cells. Nat Rev Genet (2011) 1.55
Ryanodine receptors and ventricular arrhythmias: emerging trends in mutations, mechanisms and therapies. J Mol Cell Cardiol (2006) 1.55
Dantrolene stabilizes domain interactions within the ryanodine receptor. J Biol Chem (2004) 1.52
Mouse and human induced pluripotent stem cells as a source for multipotent Isl1+ cardiovascular progenitors. FASEB J (2009) 1.43
Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor. J Biol Chem (2002) 1.34
Mechanisms and clinical management of inherited channelopathies: long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT syndrome. Heart Rhythm (2009) 1.27
Defective domain-domain interactions within the ryanodine receptor as a critical cause of diastolic Ca2+ leak in failing hearts. Cardiovasc Res (2008) 1.27
Global transcriptional profiles of beating clusters derived from human induced pluripotent stem cells and embryonic stem cells are highly similar. BMC Dev Biol (2010) 1.21
Removal of FKBP12.6 does not alter the conductance and activation of the cardiac ryanodine receptor or the susceptibility to stress-induced ventricular arrhythmias. J Biol Chem (2007) 1.17
Ryanodine receptor and calsequestrin in arrhythmogenesis: what we have learnt from genetic diseases and transgenic mice. J Mol Cell Cardiol (2008) 1.17
Probing a putative dantrolene-binding site on the cardiac ryanodine receptor. Biochem J (2005) 1.15
Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia in a RyR2(R2474S/+) knock-in mouse model. Circ J (2010) 1.12
From the ryanodine receptor to cardiac arrhythmias. Circ J (2009) 1.11
Cardiac calcium signalling. Biochem Soc Trans (2003) 1.09
Dynamic, inter-subunit interactions between the N-terminal and central mutation regions of cardiac ryanodine receptor. J Cell Sci (2010) 1.07
Postulated role of inter-domain interaction within the ryanodine receptor in Ca(2+) channel regulation. Trends Cardiovasc Med (2000) 1.06
Localization of the dantrolene-binding sequence near the FK506-binding protein-binding site in the three-dimensional structure of the ryanodine receptor. J Biol Chem (2011) 1.05
Reversing advanced heart failure by targeting Ca2+ cycling. Annu Rev Med (2008) 1.01
Ryanodine receptor mutations in arrhythmia: The continuing mystery of channel dysfunction. FEBS Lett (2010) 0.89
Exercise-induced ventricular arrhythmias in patients with no structural cardiac disease. Annu Rev Med (2006) 0.82
Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature (2005) 9.44
Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med (2010) 9.19
Multipotent embryonic isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. Cell (2006) 7.21
Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet (2006) 5.29
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Subunit composition of mammalian transient receptor potential channels in living cells. Proc Natl Acad Sci U S A (2002) 3.88
Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med (2007) 3.84
Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA (2006) 3.78
Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA (2005) 3.67
The renewal and differentiation of Isl1+ cardiovascular progenitors are controlled by a Wnt/beta-catenin pathway. Cell Stem Cell (2007) 3.54
Increased vascular smooth muscle contractility in TRPC6-/- mice. Mol Cell Biol (2005) 3.28
Mitochondria are morphologically and functionally heterogeneous within cells. EMBO J (2002) 2.97
A randomized trial of coronary stenting versus balloon angioplasty as a rescue intervention after failed thrombolysis in patients with acute myocardial infarction. J Am Coll Cardiol (2004) 2.67
A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease. J Am Coll Cardiol (2008) 2.49
TRPM5 is a voltage-modulated and Ca(2+)-activated monovalent selective cation channel. Curr Biol (2003) 2.45
Islet1 cardiovascular progenitors: a single source for heart lineages? Development (2008) 2.39
Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol (2008) 2.38
Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation (2012) 2.32
TRPM3 is a nociceptor channel involved in the detection of noxious heat. Neuron (2011) 2.31
Pressure-induced and store-operated cation influx in vascular smooth muscle cells is independent of TRPC1. Pflugers Arch (2007) 2.17
Melanocortin-4 receptor gene variant I103 is negatively associated with obesity. Am J Hum Genet (2004) 2.17
Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnesemia with secondary hypocalcemia. Proc Natl Acad Sci U S A (2004) 2.17
Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. Lancet (2011) 2.10
The role of inositol 1,4,5-trisphosphate receptors in Ca(2+) signalling and the generation of arrhythmias in rat atrial myocytes. J Physiol (2002) 2.05
Human amniotic fluid-derived stem cells are rejected after transplantation in the myocardium of normal, ischemic, immuno-suppressed or immuno-deficient rat. J Mol Cell Cardiol (2006) 1.99
Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol (2010) 1.93
Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange. Proc Natl Acad Sci U S A (2006) 1.89
Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J (2009) 1.81
Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J (2007) 1.76
Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol (2009) 1.73
Gq-coupled receptors as mechanosensors mediating myogenic vasoconstriction. EMBO J (2008) 1.71
Prognostic value of sensitive troponin T in patients with stable and unstable angina and undetectable conventional troponin. Am Heart J (2011) 1.70
Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation (2009) 1.69
TRPM5, a taste-signaling transient receptor potential ion-channel, is a ubiquitous signaling component in chemosensory cells. BMC Neurosci (2007) 1.69
First quantification of alpha-Gal epitope in current glutaraldehyde-fixed heart valve bioprostheses. Xenotransplantation (2013) 1.62
N-linked protein glycosylation is a major determinant for basal TRPC3 and TRPC6 channel activity. J Biol Chem (2003) 1.59
ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. Eur Heart J (2010) 1.56
Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions. Circulation (2006) 1.55
TRPM6 and TRPM7--Gatekeepers of human magnesium metabolism. Biochim Biophys Acta (2007) 1.51
Sustained activity of calcium release-activated calcium channels requires translocation of mitochondria to the plasma membrane. J Biol Chem (2006) 1.48
One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial. EuroIntervention (2013) 1.47
Tbx20 regulates a genetic program essential to adult mouse cardiomyocyte function. J Clin Invest (2011) 1.46
Platelet count/spleen diameter ratio for non-invasive diagnosis of oesophageal varices: is it useful in compensated cirrhosis? Dig Liver Dis (2012) 1.46
Arrhythmia causes lipid accumulation and reduced glucose uptake. Basic Res Cardiol (2015) 1.45
Bare metal vs. drug-eluting stents for extracranial vertebral artery disease: a meta-analysis of nonrandomized comparative studies. J Endovasc Ther (2014) 1.43
Insights into the molecular nature of magnesium homeostasis. Am J Physiol Renal Physiol (2004) 1.43
Mouse and human induced pluripotent stem cells as a source for multipotent Isl1+ cardiovascular progenitors. FASEB J (2009) 1.43
Alpha-Gal detectors in xenotransplantation research: a word of caution. Xenotransplantation (2012) 1.42
Gene transfer of the pancaspase inhibitor P35 reduces myocardial infarct size and improves cardiac function. J Mol Med (Berl) (2005) 1.42
Triple antithrombotic management after stent implantation: when and how? Heart (2009) 1.42
Cation channels of the transient receptor potential superfamily: their role in physiological and pathophysiological processes of smooth muscle cells. Pharmacol Ther (2006) 1.41
Melanocortin-4 receptor gene: case-control study and transmission disequilibrium test confirm that functionally relevant mutations are compatible with a major gene effect for extreme obesity. J Clin Endocrinol Metab (2003) 1.40
Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age. Catheter Cardiovasc Interv (2013) 1.40
EBF2 regulates osteoblast-dependent differentiation of osteoclasts. Dev Cell (2005) 1.40
The diacylgylcerol-sensitive TRPC3/6/7 subfamily of cation channels: functional characterization and physiological relevance. Pflugers Arch (2005) 1.40
5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol (2010) 1.39
Patterns of presentation and outcomes of patients with acute coronary syndromes. Cardiology (2009) 1.39
Correlates of poor outcome among patients with bleeding after coronary interventions. Coron Artery Dis (2014) 1.39
2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents. J Am Coll Cardiol (2010) 1.38
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med (2008) 1.37
Mechanisms underlying the neuronal calcium sensor-1-evoked enhancement of exocytosis in PC12 cells. J Biol Chem (2002) 1.28
Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response. FASEB J (2008) 1.28
In vivo TRPC functions in the cardiopulmonary vasculature. Cell Calcium (2007) 1.26
Activation of TRPC6 channels is essential for lung ischaemia-reperfusion induced oedema in mice. Nat Commun (2012) 1.25
Reduced cardiac L-type Ca2+ current in Ca(V)beta2-/- embryos impairs cardiac development and contraction with secondary defects in vascular maturation. Circ Res (2006) 1.24
Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. Circ Cardiovasc Interv (2010) 1.24